Estrone-3-Glucuronide ELISA Kit

• 価格
• 製品情報
• 製品詳細
• 文献

価格

目次に戻る

製品情報

Estrone-3-glucuronide is the predominant metabolite of estradiol in urine and a urinary marker for the fertile window in women. Measurement of urinary glucuronides is a convenient, non-invasive method for detecting reproductive hormone levels compared to measuring plasma levels. Estrone-3-glucuronide, along with pregnanediol-3-glucuronide, are indicators of female reproductive health. Literature has shown high serum estrone levels, which directly correlate to urinary estrone-3-glucuronide levels, are associated with estrogen receptor-positive breast cancers. Hormone receptor status is the main factor in planning treatment and can be treated with hormone therapies, including tamoxifen and aromatase inhibitors. In addition to its role in breast cancer, circulating estrogens, including estrone metabolized from oral hormone replacement therapy, have been shown to increase thrombin generation leading to higher risk for blood clots, myocardial infarctions, deep vein thrombosis and strokes.

目次に戻る

製品詳細

name	Estrone-3-Glucuronide ELISA Kit
Synonyms	Estrone-3-Glucuronide EIA Kit E1G
Limit of Detection	6.6 pg/ml (overnight); 10.1 pg/ml (rapid)
Assay Range	2.7-6,000 pg/ml
Sensitivity	23.2 pg/ml (overnight); 36.1 pg/ml (rapid)
Mid-point	125.6 pg/ml (overnight); 246.8 pg/ml (rapid)
Cross Reactivity	(100%) Estrone-3-Glucuronide (133%) Estrone Sulfate (0.1%) Estradiol Sulfate (0.008%) Progesterone (0.004%) Estriol ( ( ( (66%) Estrone (0.0004%) DHEA Sulfate (0.13%) Estradiol ( Show all 12 Hide all but first 3
Storage	-20°C
Shipping	Wet ice in continental US; may vary elsewhere
Stability	≥ 1 year

目次に戻る

文献

1. Eichner, S.F., and Timpe, E.M. Urinary-based ovulation and pregnancy: Point-of-care testing. Ann. Pharmacother. 38(2), 325-331 (2004).

2. O'Connor, K.A., Brindle, E., Holman, D.J., et al. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research. Clin. Chem. 49(7), 1139-1148 (2003).

3. Miyoshi, Y., Tanji, Y., Taguchi, T., et al. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin. Cancer Res. 9(6), 2229-2233 (2003).

4. Bagot, C.N., Marsh, M.S., Whitehead, M.I., et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapyexa. J. Thromb. Haemost. 8(8), 1736-1744 (2010).

5. Karim, R.M., Mack, W.J., Hodis, H.N., et al. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women. J. Clin. Endocrinol. Metab. 94(11), 4136-4143 (2009).

6. Dong, M., Mu, N., Ren, F., et al. Prospective study of effects of endogenous estrogens on myocardial no-reflow risk in postmenopausal women with acute myocardial infarction. J. Interv. Cardiol. 27(5), 437-443 (2014).

目次に戻る